JOHNSON & JOHNSON is 93.8x more valuable than Terns Pharmaceuticals, Inc. by market capitalization ($573.98 B vs $6.12 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TERN | JNJ |
|---|---|---|
| Market cap | $6.12 B | $573.98 B |
| US-listed rank | #1249 | #20 |
| Revenue (latest FY) | $0.00 | $94.19B |
| Net income (latest FY) | -$96.21M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 430 | 984 |
JOHNSON & JOHNSON is 93.8x more valuable than Terns Pharmaceuticals, Inc. by market capitalization ($573.98 B vs $6.12 B).
In their latest fiscal years, Terns Pharmaceuticals, Inc. reported $0.00 in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Terns Pharmaceuticals, Inc. and JOHNSON & JOHNSON, or browse the full rankings.